Ovid Therapeutics Inc (OVID) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Ovid Therapeutics Inc stock $1.41, price $2.40, that is 41.3% below the price, quality 59 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Ovid Therapeutics Inc
OVID · USFar too expensive (fair value 41% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.2550 – $4.04 · fair‑value band $1.06 – $1.76 · the $2.40 price screens above the $1.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Ovid Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Show moreShow less
The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Stock analysis
Ovid Therapeutics Inc (OVID) currently trades at $2.40, while our estimate is $1.41, 41% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.06 (bear) to $1.76 (bull), the price of $2.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Ovid Therapeutics Inc reported revenue of $7.3M in FY2025 versus $208M in FY2021, a compound −56.8%/yr. Reported net income was −$17.4M in FY2025.
Key figures
Market cap $437M Small · EPS (TTM) $−0.1500 · Return on equity −35.4% · Return on assets (EBIT) −21.7% (5-year average) · Operating margin −4,694% · Revenue growth (YoY) −88.3% · Free cash flow −$38.3M · Net debt $266K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 97% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, OVID screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- SaleJeffrey A RonaCBFO8,541 shares at $1.45$12,384Feb 23, 2026
- SaleMargaret A. AlexanderPresident and CEO, Director11,656 shares at $1.45$16,901Feb 23, 2026
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Ovid Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs OVID |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs OVID |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs OVID |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs OVID |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs OVID |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs OVID |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs OVID |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs OVID |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs OVID |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs OVID |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ovid Therapeutics Inc (OVID) overvalued or undervalued?
What is the fair value of OVID?
What is the quality score of OVID?
What is the price target for Ovid Therapeutics Inc (OVID)?
What is the Ovid Therapeutics Inc stock forecast for 2026?
What is the intrinsic value of Ovid Therapeutics Inc (OVID)?
Is Ovid Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of OVID?
How much is Ovid Therapeutics Inc worth?
What do the bullish and bearish scenarios say about OVID?
How solid is the balance sheet of Ovid Therapeutics Inc (OVID)?
How far is OVID from its 52-week high?
Which stocks are comparable to Ovid Therapeutics Inc?
Is Ovid Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Ovid Therapeutics Inc (OVID)?
What should I pay attention to with Ovid Therapeutics Inc right now?
Key figures of Ovid Therapeutics Inc
How large is the market capitalisation of Ovid Therapeutics Inc (OVID)?
What are the earnings per share of Ovid Therapeutics Inc (OVID)?
What is the return on equity of Ovid Therapeutics Inc (OVID)?
What is the EBIT return on assets of Ovid Therapeutics Inc (OVID)?
What is the operating margin of Ovid Therapeutics Inc (OVID)?
How fast is revenue growing at Ovid Therapeutics Inc (OVID)?
How much free cash flow does Ovid Therapeutics Inc (OVID) generate?
How much net debt does Ovid Therapeutics Inc (OVID) carry?
Watch Ovid Therapeutics Inc in the live analysis
One click puts Ovid Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.